{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:58:09Z","timestamp":1790963889993,"version":"4.1.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-2019Genecast-043"],"award-info":[{"award-number":["Y-2019Genecast-043"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-HR2019-0182"],"award-info":[{"award-number":["Y-HR2019-0182"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","award":["2024RC3042"],"award-info":[{"award-number":["2024RC3042"]}],"id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ31092"],"award-info":[{"award-number":["2021JJ31092"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2025JJ20077"],"award-info":[{"award-number":["2025JJ20077"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ31048"],"award-info":[{"award-number":["2021JJ31048"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ6662"],"award-info":[{"award-number":["2024JJ6662"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M753679"],"award-info":[{"award-number":["2024M753679"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403920"],"award-info":[{"award-number":["82403920"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874073"],"award-info":[{"award-number":["81874073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173342"],"award-info":[{"award-number":["82173342"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372629"],"award-info":[{"award-number":["81372629"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772627"],"award-info":[{"award-number":["81772627"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974384"],"award-info":[{"award-number":["81974384"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xcrm.2026.102728","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:31:38Z","timestamp":1775575898000},"page":"102728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives"],"prefix":"10.1016","volume":"7","author":[{"given":"Jiang","family":"Fei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-723X","authenticated-orcid":false,"given":"Shan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102728_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102728_bib2","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102728_bib3","first-page":"5248","article-title":"A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer","volume":"58","author":"Boland","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib4","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102728_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib6","unstructured":"Rectal cancer, version 3, 2025 clinical practice guidelines in oncology (NCCN Guidelines)."},{"key":"10.1016\/j.xcrm.2026.102728_bib7","unstructured":"Colon cancer, version 4, 2025 clinical practice guidelines in oncology (NCCN Guidelines)."},{"key":"10.1016\/j.xcrm.2026.102728_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2019.04.003","article-title":"Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy","volume":"76","author":"Ciardiello","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2026.102728_bib10","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.xcrm.2026.102728_bib11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2023.41.4_suppl.187","article-title":"Comparative analysis of tumor immune microenvironment in primary tumors vs metastatic tissue in microsatellite stable metastatic colorectal cancer","volume":"41","author":"Fakih","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study","volume":"40","author":"Lenz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.annonc.2024.05.013","volume":"35","author":"Lonardi","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102728_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.2024.42.3_suppl.121","article-title":"Short course immunotherapy as curative-intent treatment in stage I-III dMMR rectal cancer","volume":"42","author":"Pfeiffer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib16","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study","volume":"40","author":"Verschoor","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib17","doi-asserted-by":"crossref","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib18","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1016\/j.annonc.2024.08.572","article-title":"503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study","volume":"35","author":"De Gooyer","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib19","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.annonc.2024.08.611","article-title":"542P Long-term outcomes of neoadjuvant toripalimab with or without celecoxib in patients with dMMR\/MSI-H locally advanced colorectal cancer: 3-month treatment cohort of the randomized phase II PICC trial","volume":"35","author":"Hu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib20","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.annonc.2024.05.254","article-title":"247P Radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: The TARZAN study","volume":"35","author":"de Gooyer","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib21","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/JCO.2024.42.16_suppl.3505","article-title":"Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high\/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study","volume":"42","author":"Xu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib22","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1","article-title":"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)","volume":"43","author":"Sinicrope","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib24","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/j.annonc.2024.08.613","article-title":"544P Nivolumab plus ipilimumab in microsatellite instability high (MSI)\/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final survival analysis and prognostic evaluation of GDF-15 in the phase II GERCOR NIPICOL study","volume":"35","author":"Depotte","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib25","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1200\/JCO.2023.41.16_suppl.2608","article-title":"The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR\/MSI-H colorectal cancer","volume":"41","author":"Gandini","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib26","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1158\/1078-0432.CCR-21-0163","article-title":"Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases","volume":"27","author":"Kanikarla Marie","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2025.43.4_suppl.207","article-title":"Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update","volume":"43","author":"Hissong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib28","doi-asserted-by":"crossref","first-page":"LBA8","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA8","article-title":"Results from a phase 1a\/1b study of botensilimab (BOT), a novel innate\/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)","volume":"41","author":"El-Khoueiry","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib29","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1200\/JCO.2025.43.16_suppl.3579","article-title":"Safety and efficacy of ADG126 (an anti-CTLA-4 masking antibody) in combination with pembrolizumab: Updated results of phase 1b\/2 study in advanced MSS CRC","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib30","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2025.43.16_suppl.3553","article-title":"Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti\u2013CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC","volume":"43","author":"Fakih","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib33","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2022.40.16_suppl.3509","article-title":"Phase II study of nivolumab in combination with FOLFOXIRI\/bevacizumab as first-line treatment in patients with advanced colorectal cancer RAS\/BRAF mutated (mut): NIVACOR trial (GOIRC-03-2018)","volume":"40","author":"Damato","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib34","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1200\/JCO.2025.43.16_suppl.3599","article-title":"Neoadjuvant mFOLFOXIRI chemotherapy with or without cadonilimab versus mFOLFOX6 alone in locally advanced colorectal cancer: A randomized phase II study (OPTICAL2)","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib35","doi-asserted-by":"crossref","first-page":"e15547","DOI":"10.1200\/JCO.2024.42.16_suppl.e15547","article-title":"Updated efficacy and safety results from the phase Ib\/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib36","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1016\/j.annonc.2024.08.608","article-title":"539P Hepatic arterial infusion chemotherapy combined with sintilimab and regorafenib as adjuvant therapy for colorectal liver metastasis patients with high risk of recurrent: A single-arm, phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib37","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","article-title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","volume":"29","author":"Thibaudin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib38","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.annonc.2024.05.053","article-title":"42P Neoadjuvant tislelizumab combined with CAPOX for MSS\/pMMR high-risk locally advanced colon cancer: A single-arm, exploratory phase II clinical study","volume":"35","author":"Lin","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib39","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.annonc.2024.05.250","article-title":"243P Neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: Preliminary results from a randomized, open-label phase II trial","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib40","first-page":"e15660","article-title":"Rectal arterial infusion chemotherapy combined with anti-PD1 antibody for microsatellite stable locally advanced rectal cancer: The effectiveness and safety of a single-arm, phase II study","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cam4.3630","article-title":"A phase 2 trial of trifluridine\/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer","volume":"10","author":"Patel","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13148-021-01226-y","article-title":"Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis","volume":"14","author":"Kuang","year":"2022","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.xcrm.2026.102728_bib43","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.21.02583","article-title":"Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial","volume":"40","author":"Morano","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib44","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1016\/j.annonc.2023.09.1747","article-title":"A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS\/pMMR metastatic colorectal cancer","volume":"34","author":"Wang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2021.39.3_suppl.7","article-title":"Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS\/NRAS\/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"39","author":"Lee","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib47","doi-asserted-by":"crossref","first-page":"S1433","DOI":"10.1016\/j.annonc.2024.10.097","article-title":"75P Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib48","doi-asserted-by":"crossref","first-page":"S1508","DOI":"10.1016\/j.annonc.2023.10.232","article-title":"Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)","volume":"34","author":"Xu","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115111","article-title":"Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial","volume":"213","author":"Xiao","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2022.40.4_suppl.135","article-title":"Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient\/microsatellite stable (pMMR\/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results","volume":"40","author":"Saeed","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib51","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2021.39.3_suppl.94","article-title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the colorectal cancer cohort","volume":"39","author":"Gomez-Roca","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib53","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005332","article-title":"Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)","volume":"10","author":"Johnson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib55","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib56","first-page":"e15531","article-title":"Sintilimab in combination with cetuximab and chemotherapy as first-line treatment for RAS\/BRAF wild-type advanced colorectal cancer (CALLIOPSIS): An open-label, non-comparative, phase 1b\/2 dose escalation and expansion trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib57","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1200\/JCO.2024.42.16_suppl.3563","article-title":"Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer","volume":"42","author":"Yuan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib58","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1016\/j.annonc.2024.08.571","article-title":"502O Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial","volume":"35","author":"Tougeron","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib59","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.medj.2024.05.009","article-title":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2\/3 trial","volume":"5","author":"Wang","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.xcrm.2026.102728_bib60","first-page":"e15633","article-title":"Neoadjuvant therapy with mFOLFOXIRI combined with camrelizumab and bevacizumab for microsatellite stable, locally advanced rectal cancer: A single-arm, open-label phase II study","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib61","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.annonc.2024.05.052","article-title":"41P Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS\/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)","volume":"35","author":"Zhang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib62","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2024.42.16_suppl.3570","article-title":"Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN)","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib63","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.annonc.2024.05.059","article-title":"48P Efficacy and safety of combination regimen of irinotecan plus cetuximab and envafolimab (ICE regimen) in refractory RAS\/BRAF WT\/MSS mCRC","volume":"35","author":"Zhang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib64","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1038\/s41467-024-51536-x","article-title":"Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102728_bib65","doi-asserted-by":"crossref","first-page":"LBA3516","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA3516","article-title":"JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study","volume":"43","author":"Xu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1825","article-title":"635P Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study","volume":"34","author":"van den Eynde","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2026.102728_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.2023.41.4_suppl.161","article-title":"Phase Ib of pembrolizumab (pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MMR-proficient (pMMR) colorectal cancer (CRC): Final results","volume":"41","author":"Deming","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1285","article-title":"2257P Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort","volume":"34","author":"Levy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib70","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2019.37.15_suppl.3514","article-title":"A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC)","volume":"37","author":"Parikh","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib71","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1078-0432.CCR-20-2474","article-title":"Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer","volume":"27","author":"Segal","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib72","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.annonc.2024.05.255","article-title":"248P Preliminary results from CA209-8M4: A phase II trial evaluating the addition of nivolumab (nivo) to total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC)","volume":"35","author":"Brenner","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf057","article-title":"Impact of PD1 blockade added to neoadjuvant chemoradiotherapy on rectal cancer surgery: post-hoc analysis of the randomized POLARSTAR trial","volume":"112","author":"Pang","year":"2025","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.xcrm.2026.102728_bib74","article-title":"601P Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH","volume":"34","author":"Wang","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib75","doi-asserted-by":"crossref","first-page":"S1435","DOI":"10.1016\/j.annonc.2024.10.102","article-title":"80P Split-course hypofraction radiotherapy combined with chemotherapy and tislelizumab as preoperative treatment for locally advanced rectal cancer: Interim analysis of a prospective, single-arm phase II trial","volume":"35","author":"Zheng","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib76","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2025.43.16_suppl.3523","article-title":"Immunotherapy combined with hypofractionated radiotherapy and chemotherapy for locally recurrent rectal cancer (TORCH-R): A prospective, single-arm, two-cohort, phase II trial","volume":"43","author":"Wu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib77","doi-asserted-by":"crossref","first-page":"e15621","DOI":"10.1200\/JCO.2025.43.16_suppl.e15621","article-title":"Phase II trial of anti PD-1 monoclonal antibody and FOLFOXIRI combined with long-course radiotherapy as the total neoadjuvant treatment for proficient mismatch repair, locally advanced, low rectal cancer (PANFORTE)","volume":"43","author":"Peng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib78","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/j.annonc.2024.08.639","article-title":"570P A phase II clinical study of fruquintinib (Fru) combined with toripalimab (Tor) and short-course radiotherapy (SCRT) as neoadjuvant therapy for locally advanced rectal cancer (LARC)","volume":"35","author":"Chen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib79","doi-asserted-by":"crossref","first-page":"S449","DOI":"10.1016\/j.annonc.2024.08.606","article-title":"537P Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)","volume":"35","author":"Chen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib80","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.2023.41.4_suppl.150","article-title":"Fruquintinib combined with tislelizumab and SBRT as a later-line therapy in microsatellite stability (MSS) metastatic colorectal cancer (mCRC): Results from the FRUIT trial","volume":"41","author":"Yuan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib81","first-page":"e15553","article-title":"Short-course radiotherapy followed by CAPOX combined with tislelizumab and bevacizumab or cetuximab for treatment-naive unresectable metastatic rectal cancer (UNION mRC)","volume":"43","author":"Lin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib82","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1200\/JCO.2025.43.4_suppl.192","article-title":"Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT)","volume":"43","author":"Lin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib83","first-page":"e15659","article-title":"A phase II study of short-course radiotherapy followed by sintilimab, anlotinib combined with CAPOX as neoadjuvant treatment for locally advanced MSS\/pMMR rectal cancer (ZZU-1 study)","volume":"43","author":"Zhao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib84","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib85","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA248","article-title":"Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study","volume":"43","author":"Segal","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib86","doi-asserted-by":"crossref","first-page":"S435","DOI":"10.1016\/j.annonc.2024.08.583","article-title":"514MO The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC)","volume":"35","author":"Deng","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib87","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2025.43.16_suppl.104","article-title":"Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer","volume":"43","author":"Lin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib88","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1200\/JCO.2022.40.16_suppl.3598","article-title":"Phase I\/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer","volume":"40","author":"Morris","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib89","first-page":"272","article-title":"A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer","volume":"23","author":"Hernando-Calvo","year":"2024","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib90","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1016\/j.annonc.2023.09.1810","article-title":"619P Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients: Interim results from the GOBLET study","volume":"34","author":"Ungerechts","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib92","doi-asserted-by":"crossref","first-page":"e14665","DOI":"10.1200\/JCO.2023.41.16_suppl.e14665","article-title":"Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR\/MSI-h colorectal cancer","volume":"41","author":"Overman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib93","doi-asserted-by":"crossref","first-page":"LBA13","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA13","article-title":"A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC)","volume":"43","author":"Hecht","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib94","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1200\/JCO.2024.42.16_suppl.3594","article-title":"A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301)","volume":"42","author":"Hubbard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib95","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41392-024-01788-2","volume":"9","author":"Pan","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.102728_bib96","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1200\/JCO.2023.41.16_suppl.3599","article-title":"Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study","volume":"41","author":"Palmieri","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib97","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.annonc.2023.09.1831","article-title":"641P Phase I\/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR\/MSS) chemorefractory metastatic colorectal cancer (mCRC)","volume":"34","author":"Pietrantonio","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102315","article-title":"Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)","volume":"66","author":"Zhao","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.xcrm.2026.102728_bib100","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.annonc.2024.05.019","article-title":"8MO Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient and deficient colorectal cancer: NEST-1 clinical trial","volume":"35","author":"Kasi","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib101","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8707","article-title":"High-dose vitamin C enhances cancer immunotherapy","volume":"12","author":"Magr\u00ec","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib102","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1200\/JCO.2024.42.16_suppl.3556","article-title":"Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites","volume":"42","author":"Fakih","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib103","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102728_bib104","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-016-0163-8","article-title":"5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers","volume":"4","author":"Van Der Kraak","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib106","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.102728_bib107","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.2010.211722","article-title":"Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice","volume":"60","author":"Gonzalez-Aparicio","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2026.102728_bib108","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.ejca.2010.03.005","article-title":"Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)","volume":"46","author":"Correale","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib109","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen","volume":"76","author":"Limagne","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib110","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1007\/s00262-021-02986-5","article-title":"A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186","volume":"70","author":"Herting","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2026.102728_bib111","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/ijc.26181","article-title":"Cetuximab +\/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro","volume":"130","author":"Correale","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib112","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/2326-6066.CIR-19-0228","article-title":"Trifluridine\/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages","volume":"7","author":"Limagne","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib113","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/0008-5472.CAN-15-2125","article-title":"Combining Epigenetic and Immunotherapy to Combat Cancer","volume":"76","author":"Chiappinelli","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib114","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001696","article-title":"Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma","volume":"9","author":"Que","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225715","article-title":"Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy","volume":"13","author":"Ciardiello","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102728_bib116","first-page":"141","article-title":"Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival","volume":"21","author":"Ciardiello","year":"2022","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.xcrm.2026.102728_bib117","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib118","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.1016\/j.annonc.2022.07.565","article-title":"Targeting adenosine (ADO) to improve the efficacy of combinations of cetuximab (CET) and immunotherapy in EGFRvIII MSS colorectal cancer (CRC)","volume":"33","author":"Shi","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib119","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2019.00849","article-title":"Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors","volume":"9","author":"Garc\u00eda-Foncillas","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib120","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3858\/emm.2011.43.10.063","article-title":"One target, different effects: a comparison of distinct therapeutic antibodies against the same targets","volume":"43","author":"Shim","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib121","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib122","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1096-1096","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Gabrilovich","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay0555","article-title":"VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers","volume":"4","author":"Kim","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2026.102728_bib124","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib125","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102728_bib126","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102728_bib127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102728_bib128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8(+) T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102728_bib129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ccell.2020.11.004","article-title":"MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway","volume":"39","author":"Guan","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.102728_bib130","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib131","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102728_bib132","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2026.102728_bib133","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102728_bib134","first-page":"e15644","article-title":"Neoadjuvant chemoradiotherapy plus PD-1 inhibitor (tislelizumab) for high risk and MRF+ low locally advanced rectal cancer","volume":"43","author":"Lin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib135","first-page":"e15645","article-title":"Efficacy of long-course versus short-course chemoradiotherapy combined with immunotherapy for pMMR\/MSS rectal adenocarcinoma: A real-world cohort study","volume":"43","author":"Huang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib136","doi-asserted-by":"crossref","first-page":"e15559","DOI":"10.1200\/JCO.2023.41.16_suppl.e15559","article-title":"Efficacy and safety of radiation therapy combined with anti-angiogenic agentsand immunotherapy for MSS\/pMMR metastatic colorectal cancer: A real-world study","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib137","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1200\/JCO.2025.43.16_suppl.3550","article-title":"Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer (mCRC): Whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study","volume":"43","author":"Eng","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib138","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib139","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102728_bib140","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2025.43.16_suppl.3541","article-title":"Safety and efficacy of anti-CEA CAR-T cells to prolong relapse-free survival of colorectal cancer liver metastases patients after radical resection","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib141","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.2025.43.16_suppl.3581","article-title":"A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States","volume":"43","author":"Schlechter","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib142","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib143","doi-asserted-by":"crossref","first-page":"TPS272","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS272","volume":"41","author":"Kopetz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib144","doi-asserted-by":"crossref","first-page":"S625","DOI":"10.1016\/j.annonc.2023.09.2168","volume":"34","author":"Olszanski","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.2023.41.4_suppl.46","article-title":"Microsatellite instability (MSI), mismatch repair (MMR), and tumor mutational burden (TMB) as predictive biomarkers for immune checkpoint inhibitor (ICI) effectiveness in real-world patients with metastatic colorectal cancer (mCRC)","volume":"41","author":"Ellis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib146","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.annonc.2023.05.010","article-title":"Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability","volume":"34","author":"Ratovomanana","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib147","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2023.41.4_suppl.202","article-title":"Analysis of HLA gene expression in patients with dMMR\/MSI-H colorectal carcinoma resistant to immune checkpoint inhibitors","volume":"41","author":"Lenz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib148","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JCO.2025.43.4_suppl.270","article-title":"Prediction of immunotherapy response in deficient mismatch repair colorectal cancers using an immune-enhanced exome and transcriptome platform","volume":"43","author":"Sinicrope","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib149","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.annonc.2024.05.132","article-title":"121P Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)\/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)","volume":"35","author":"Vaghi","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib150","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/j.annonc.2023.09.1818","article-title":"Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers","volume":"34","author":"Stemmer","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib151","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2025.43.16_suppl.3559","article-title":"The efficacy of watch and wait strategy or surgery after neoadjuvant immunotherapy for locally advanced colorectal cancer with dMMR\/MSI-H guided by ctDNA dynamic monitoring (WINDOW): A single-center, open-label, prospective, phase II study","volume":"43","author":"Zhang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1820","article-title":"630P Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI\/dMMR colorectal cancer (mCRC MSI)","volume":"34","author":"Barbe","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib153","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1158\/1078-0432.CCR-21-0529","article-title":"Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer","volume":"27","author":"Marisa","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102728_bib154","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/jamaoncol.2019.2963","article-title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1470-2045(22)00783-5","article-title":"Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study","volume":"24","author":"Wang","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib156","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib157","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2025.43.16_suppl.3547","article-title":"Prognostic and predictive role of HLA supertypes in pMMR mCRC patients receiving FOLFOXIRI\/bev \u00b1 atezolizumab in the AtezoTRIBE study","volume":"43","author":"Rossini","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib158","doi-asserted-by":"crossref","first-page":"S699","DOI":"10.1016\/j.annonc.2022.07.495","article-title":"Novel potential predictive biomarker to immunotherapy (Io) treatment in metastatic colorectal cancer (mCRC) patients: The role of the VHIO immune gene-expression signature (VIGex)","volume":"33","author":"Gonzalez","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1822","article-title":"632P Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab","volume":"34","author":"Meltzer","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib160","doi-asserted-by":"crossref","first-page":"S456","DOI":"10.1016\/j.annonc.2024.08.620","article-title":"551P Efficacy prediction of chemoradiotherapy plus anti-PD-1\/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer","volume":"35","author":"Tang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib161","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2025.43.4_suppl.132","article-title":"Adverse events (AEs) \u2013derived biomarker in predicting clinical outcomes in patients with colorectal cancer (CRC) treated with immunotherapy (IC)","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib162","doi-asserted-by":"crossref","first-page":"e15534","DOI":"10.1200\/JCO.2023.41.16_suppl.e15534","article-title":"Immune activation-related risk score: A new tool to predict prognosis and immunotherapy applicability in colorectal cancer","volume":"41","author":"Zhu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib163","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.2024.42.3_suppl.213","article-title":"Correlation of exploration of immune profile and genomic with microsatellite stable\/tumor mutational burden-low colorectal cancer","volume":"42","author":"Abushukair","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib164","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","article-title":"Evolution of Metastases in Space and Time under Immune Selection","volume":"175","author":"Angelova","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102728_bib165","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.annonc.2024.05.067","volume":"35","author":"Formica","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib166","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2025.43.4_suppl.163","article-title":"Immunotherapy outcomes in dMMR\/MSI-H and\/or TMB-H metastatic colorectal cancer (CRC) with peritoneal metastases (PM)","volume":"43","author":"Mosalem","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib167","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2025.43.4_suppl.187","article-title":"Immunotherapy for MSI-H colorectal cancer with isolated peritoneal metastases","volume":"43","author":"Metzger","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib168","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1016\/j.annonc.2024.08.612","article-title":"543P Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)","volume":"35","author":"Ree","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib169","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2025.43.16_suppl.3533","article-title":"Metastatic site pattern as predictor of outcome of first-line alternating oxaliplatin-based chemotherapy and nivolumab for patients with microsatellite-stable (MSS) colorectal cancer (CRC)","volume":"43","author":"Ree","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib170","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO.2023.41.16_suppl.3573","article-title":"Impact of WNT\/B-catenin alterations and metastasis location among patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) combinations","volume":"41","author":"Ros Monta\u00f1\u00e1","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib171","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2023.41.4_suppl.183","article-title":"Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial","volume":"41","author":"Ma","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102728_bib172","doi-asserted-by":"crossref","first-page":"S1318","DOI":"10.1016\/j.annonc.2022.07.1780","article-title":"Comutations in DNA damage repair pathway and its correlations with potential biomarkers for colorectal cancer immunotherapy in a Chinese cohort","volume":"33","author":"Shi","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912600145X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912600145X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:24:06Z","timestamp":1778919846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912600145X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S266637912600145X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102728","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102728","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102728"}}